Destiny Gastric04 DS8201-A-U306
A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen
Description:
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information